stars 1 stars 2 stars 3

Cancer meets obesity - Metabolic dysfunction (obesity. diabetes, etc.) makes cancer more aggressive. SynDevRx is pioneering the metabo-oncology field with a first-in-class therapeutic targeting cancer patients with metabolic dysfunction. This overlooked patient population is estimated at >700,000/year in the US. We are in multiple Phase 2 clinical studies in breast cancer and prostate cancer with a unique value proposition. Our lead asset 'evexomostat' has dual action - anti-angiogenic/anti-tumor plus a potent and clinically validated metabolic correction activity.

SynDevRx, Inc. Questions

The SynDevRx, Inc. annual revenue was $6 million in 2026.

James Shanahan is the Co-Founder, Chief Business Officer of SynDevRx, Inc..

6 people are employed at SynDevRx, Inc..

SynDevRx, Inc. is based in Cambridge, Massachusetts.

The NAICS codes for SynDevRx, Inc. are [32, 325, 3254, 32541].

The SIC codes for SynDevRx, Inc. are [283, 28].

Top SynDevRx, Inc. Employees

View Similar People
Learn More
How It Works
get free account
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups.
search page
Search the #1 Contact Database
Get contact details of over 700M profiles across 60M companies – all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
get contact page
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.
G2 Leader Spring 2026 G2 Best Est ROI Mid Market Spring 2026 G2 Easiest Admin Mid Market Spring 2026 G2 Most Implementable Spring 2026 G2 Best Results Mid Market Spring 2026 G2 Lead Capture Mid Market Spring 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2025
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users